Lixte Stock Financials

LIXT -  USA Stock  

USD 2.72  0.07  2.51%

Understanding current and past Lixte Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Lixte Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Lixte Biotech's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Lixte Biotech's financials over time to get the whole picture.
We recommend to make use of analysis of Lixte Biotech Hlds fundamentals to see if markets are presently mispricing the entity. We have analyzed and interpolated thirty available fundamentals for Lixte Biotech, which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Lixte Biotech Hlds financials, including its book value per share, as well as the relationship between the market capitalization and z score . Please also check out Lixte Biotech price to earning to check the company can sustain itself down the road. Use Lixte Biotech to protect your portfolios against small market fluctuations. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Lixte Biotech to be traded at $2.61 in 90 days.

Search Fundamentals 

With this module, you can analyze Lixte financials for your investing period. You should be able to track the changes in Lixte Biotech individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  Chance Of Financial Distress
Over 97
Lixte Biotech Hlds has more than 97 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Lixte Biotech stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Lixte Biotech's official financial statements usually reflect Lixte Biotech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lixte Biotech Hlds. For example, before you start analyzing numbers published by Lixte accountants, it's critical to develop an understanding of what Lixte Biotech's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Lixte Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lixte Biotech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lixte Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lixte Biotech Hlds. Please utilize our Beneish M Score to check the likelihood of Lixte Biotech's management to manipulate its earnings.

Lixte Biotech Company Summary

Lixte Biotech competes with Regeneron Pharmaceuticals, Vertex Pharmaceutic, Seagen, Beigene, and Alnylam Pharmaceuticals. Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was incorporated in 2005 and is based in East Setauket, New York. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
Business Address248 Route 25A,
Phone631 830 7092
CurrencyUSD - US Dollar

Lixte Biotech Key Financial Ratios

Generally speaking, Lixte Biotech's financial ratios allow both analysts and investors to convert raw data from Lixte Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of Lixte Biotech over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Lixte Biotech Hlds reports annually and quarterly.

Lixte Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Lixte Biotech's current stock value. Our valuation model uses many indicators to compare Lixte Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lixte Biotech competition to find correlations between indicators driving Lixte Biotech's intrinsic value. More Info.
Lixte Biotech Hlds is rated below average in working capital category among related companies. It is rated below average in market capitalization category among related companies creating about  30.60  of Market Capitalization per Working Capital.

Lixte Biotech Hlds Systematic Risk

Lixte Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lixte Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-one with a total number of output elements of fourty. The Beta measures systematic risk based on how returns on Lixte Biotech Hlds correlated with the market. If Beta is less than 0 Lixte Biotech generally moves in the opposite direction as compared to the market. If Lixte Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lixte Biotech Hlds is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lixte Biotech is generally in the same direction as the market. If Beta > 1 Lixte Biotech moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Lixte Biotech Financials

What exactly are Lixte Biotech Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Lixte Biotech's income statement, its balance sheet, and the statement of cash flows. Potential Lixte Biotech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Lixte Biotech investors may use each financial statement separately, they are all related. The changes in Lixte Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lixte Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Lixte Biotech July 29, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Lixte Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lixte Biotech Hlds. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lixte Biotech Hlds based on widely used predictive technical indicators. In general, we focus on analyzing Lixte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lixte Biotech's daily price indicators and compare them against related drivers.
Downside Deviation4.4
Information Ratio0.0388
Maximum Drawdown27.61
Value At Risk(7.27)
Potential Upside6.19
Additionally, see Stocks Correlation. Note that the Lixte Biotech Hlds information on this page should be used as a complementary analysis to other Lixte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotech Hlds price analysis, check to measure Lixte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotech is operating at the current time. Most of Lixte Biotech's value examination focuses on studying past and present price action to predict the probability of Lixte Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lixte Biotech's price. Additionally, you may evaluate how the addition of Lixte Biotech to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
The market value of Lixte Biotech Hlds is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotech's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotech's market value can be influenced by many factors that don't directly affect Lixte Biotech Hlds underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Lixte Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.